1. CMU Intellectual Repository

Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 11-19 of 19 (Search time: 0.002 seconds).
Item hits:
Issue DateTitleAuthor(s)
1-Jan-2016A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based RegimensNontiya Homkham; Tim R. Cressey; Lily Ingsrisawang; Naïm Bouazza; Chaiwat Ngampiyaskul; Suchat Hongsiriwon; Sakulrat Srirojana; Suparat Kanjanavanit; Sorakij Bhakeecheep; Sophie Le Coeur; Nicolas Salvadori; Jean Marc Treluyer; Gonzague Jourdain; Saik Urien
1-Jan-2015Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancyTim R. Cressey; Saik Urien; Edmund V. Capparelli; Brookie M. Best; Sudanee Buranabanjasatean; Aram Limtrakul; Boonsong Rawangban; Prapan Sabsanong; Jean Marc Treluyer; Gonzague Jourdain; Alice Stek; Marc Lallemant; Mark Mirochnick
2-Jan-2018Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerationsDiana F. Clarke; Martina Penazzato; Edmund Capparelli; Tim R. Cressey; George Siberry; Nandita Sugandhi; Mark Mirochnick
8-Mar-2018A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant WomenStein Schalkwijk; Rob Ter Heine; Angela C. Colbers; Alwin D.R. Huitema; Paolo Denti; Kelly E. Dooley; Edmund Capparelli; Brookie M. Best; Tim R. Cressey; Rick Greupink; Frans G.M. Russel; Mark Mirochnick; David M. Burger
1-Jan-2018Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescentsWatsamon Jantarabenjakul; Suvaporn Anugulruengkitt; Naruporn Kasipong; Narukjaporn Thammajaruk; Jiratchaya Sophonphan; Torsak Bunupuradah; Tim R. Cressey; Angela Colbers; David M. Burger; Wanatpreeya Phongsamart; Thanyawee Puthanakit; Chitsanu Pancharoen
1-Jan-2017Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patientsNaïm Bouazza; Tim R. Cressey; Frantz Foissac; Andrzej Bienczak; Paolo Denti; Helen McIlleron; David Burger; Martina Penazzato; Marc Lallemant; Edmund V. Capparelli; Jean Marc Treluyer; Saïk Urien
1-Dec-2018Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B VirusTim R. Cressey; Linda Harrison; Jullapong Achalapong; Prateep Kanjanavikai; Orada Patamasingh Na Ayudhaya; Prateung Liampongsabuddhi; Thitiporn Siriwachirachai; Chaiwat Putiyanun; Pornnapa Suriyachai; Camlin Tierney; Nicolas Salvadori; Dujrudee Chinwong; Luc Decker; Yardpiroon Tawon; Trudy V. Murphy; Nicole Ngo-Giang-Huong; George K. Siberry; Gonzague Jourdain
1-May-2019Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingStein Schalkwijk; Rob Ter Heine; Angela Colbers; Edmund Capparelli; Brookie M. Best; Tim R. Cressey; Rick Greupink; Frans G.M. Russel; José Moltó; Mark Mirochnick; Mats O. Karlsson; David M. Burger
1-Aug-2019Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIVHylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R. Cressey; Martina Penazzato; Angela Colbers; David M. Burger

Discover